162 related articles for article (PubMed ID: 9815565)
1. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant treatment of canine osteosarcoma with the human cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Jeglum KA; Santoli D
Clin Cancer Res; 1999 Jul; 5(7):1868-75. PubMed ID: 10430094
[TBL] [Abstract][Full Text] [Related]
5. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
6. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
7. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
Cesano A; Visonneau S; Santoli D
Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
[TBL] [Abstract][Full Text] [Related]
8. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
Visonneau S; Cesano A; Torosian MH; Santoli D
Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
[TBL] [Abstract][Full Text] [Related]
9. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
Cesano A; Visonneau S; Santoli D
Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
[TBL] [Abstract][Full Text] [Related]
10. Primary malignant histiocytosis of the brain in a dog.
Chandra AM; Ginn PE
J Comp Pathol; 1999 Jul; 121(1):77-82. PubMed ID: 10373296
[TBL] [Abstract][Full Text] [Related]
11. Toxicological and immunological evaluation of the MHC-non-restricted cytotoxic T cell line TALL-104.
Cesano A; Visonneau S; Wolfe JH; Jeglum KA; Fernandez J; Gillio A; O'Reilly RJ; Santoli D
Cancer Immunol Immunother; 1997 May; 44(3):125-36. PubMed ID: 9191872
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: implications for adoptive cell therapy of cancer.
Cesano A; Wortman JA; Pourdehnad M; Visonneau S; Mozley D; Bhatnagar A; Alavi A; Santoli D
Int J Oncol; 1999 Feb; 14(2):233-44. PubMed ID: 9917497
[TBL] [Abstract][Full Text] [Related]
14. [The repetitive immune cell transfer therapy combining non-myelosuppressive chemotherapy for patients with advanced and refractory cancer].
Toh U; Fujii T; Tayama K; Yanaga H; Yokoyama G; Yamaguchi M; Horiuchi H; Sasatomi T; Takamori S; Shirouzu K; Seki N; Yamana H
Gan To Kagaku Ryoho; 2004 Oct; 31(11):1649-51. PubMed ID: 15553672
[TBL] [Abstract][Full Text] [Related]
15. Intralymphatic autochthonous tumor cell vaccine in canine lymphoma.
Jeglum KA; Young KM; Barnsley K; Whereat A; McGrath D; Hutson C
J Biol Response Mod; 1986 Apr; 5(2):168-75. PubMed ID: 3734843
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.
Cesano A; Visonneau S; Rovera G; Santoli D
Anticancer Res; 1997; 17(3C):1887-92. PubMed ID: 9216640
[TBL] [Abstract][Full Text] [Related]
17. RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.
Mason NJ; Coughlin CM; Overley B; Cohen JN; Mitchell EL; Colligon TA; Clifford CA; Zurbriggen A; Sorenmo KU; Vonderheide RH
Gene Ther; 2008 Jul; 15(13):955-65. PubMed ID: 18337841
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial.
Bergman PJ; McKnight J; Novosad A; Charney S; Farrelly J; Craft D; Wulderk M; Jeffers Y; Sadelain M; Hohenhaus AE; Segal N; Gregor P; Engelhorn M; Riviere I; Houghton AN; Wolchok JD
Clin Cancer Res; 2003 Apr; 9(4):1284-90. PubMed ID: 12684396
[TBL] [Abstract][Full Text] [Related]
19. Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma.
Lupu M; Sullivan EW; Westfall TE; Little MT; Weigler BJ; Moore PF; Stroup PA; Zellmer E; Kuhr C; Storb R
J Am Vet Med Assoc; 2006 Mar; 228(5):728-32. PubMed ID: 16506937
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]